Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

133.04USD
17 Aug 2017
Change (% chg)

$-1.13 (-0.84%)
Prev Close
$134.17
Open
$134.18
Day's High
$134.74
Day's Low
$133.03
Volume
5,741,249
Avg. Vol
5,553,999
52-wk High
$137.08
52-wk Low
$109.32

Latest Key Developments (Source: Significant Developments)

Morphosys CEO sees 5 months of guselkumab royalties this year
Friday, 14 Jul 2017 05:23am EDT 

July 14 (Reuters) - Morphosys CEO tells Reuters:Says he expects royalties for 5 months this year after U.S. Approval of guselkumab.Says milestone payment for guselkumab approval is included in FY guidance, royalties are not.  Full Article

Trianni signs licensing agreement with Janssen
Wednesday, 15 Feb 2017 09:00am EST 

Trianni Inc: Trianni signs licensing agreement for transgenic mouse platform use with Janssen .Trianni - entered license agreement with Janssen Biotech for use of Trianni Mouse, a best-in-class monoclonal antibody discovery platform.  Full Article

X-Chem expands collaboration with Janssen in inflammatory diseases
Wednesday, 15 Feb 2017 08:15am EST 

Johnson & Johnson : X-Chem expands collaboration with Janssen in inflammatory diseases .X-Chem - X-Chem receives an upfront payment and research funding, and is eligible to receive additional payments.  Full Article

Integra Lifesciences says Depuy Synthes entitled to get termination fee of $60 million if co fails to complete deal
Wednesday, 15 Feb 2017 08:03am EST 

Integra Lifesciences Holdings Corp : Depuy Synthes entitled to get termination fee of $60 million if co fails to complete deal after conditions to closing are satisfied .Depuy Synthes to pay termination fee of $41.8 million if co terminates deal due to Depuy Synthes’S breach of exclusivity obligations.  Full Article

Integra Lifesciences plans to acquire Codman neurosurgery business from Johnson & Johnson for $1.045 bln
Wednesday, 15 Feb 2017 07:00am EST 

Integra Lifesciences Holdings Corp : Integra Lifesciences plans to acquire the Codman neurosurgery business from Johnson & Johnson for $1.045 billion in cash . Deal for $1.045 billion in cash . Transaction expected to be accretive to integra's adjusted earnings per diluted share by at least $0.22 in first fy . Says expects codman neurosurgery revenue to experience some initial disruption in first year of combination . Says expects codman neurosurgery revenue to grow 3% to 6% longer term . Says has obtained committed financing, subject to customary closing conditions, from BofA Merrill Lynch and JPMorgan .Deal expected to also accelerate path to achieving co's aspirational targets of $2 billion in revenue, 30% adjusted ebitda margin.  Full Article

Akebia Therapeutics provides update on Janssen deal
Monday, 13 Feb 2017 07:24am EST 

Akebia Therapeutics Inc : Akebia Therapeutics - Janssen could be eligible to receive up to aggregate of $16.5 million from co in specified development milestone payments . Akebia Therapeutics - Janssen to be eligible to receive up to $215 million from co in specified commercial milestones as well as tiered, escalating royalties . Akebia Therapeutics - unless earlier terminated, deal will expire on a product-by-product and country-by-country basis upon expiration of last royalty term .Akebia Therapeutics-co may terminate deal in its entirety or only with respect to particular licensed compound upon 180 days' prior written notice to Janssen.  Full Article

Akebia to pay Janssen to access come intellectual property
Monday, 13 Feb 2017 07:00am EST 

Akebia Therapeutics Inc - : Will pay Janssen $1.0 million in cash to access their collection of hundreds of HIF-targeted compounds, associated intellectual property . Co obtains worldwide rights to akb-5169, a non-absorbed oral HIF stabilizer in preclinical development for treatment of IBD . Johnson & Johnson innovation has opportunity to take ownership interest in co through common stock purchase warrant issued by co to JJDC . JJDC can take ownership interest in co through common stock purchase warrant issued by co to JJDC for 509,611 shares of co's common stock .Warrant exercisable by JJDC, in whole or in part, at any time prior to 5th anniversary of date of issuance with payment to co of up to $5 million.  Full Article

Janssen Therapeutics receives funding from a special RFA
Tuesday, 25 Oct 2016 08:00am EDT 

Janssen Therapeutics- :Janssen Therapeutics - Recipients of funding from a special RFA in support of treatment for Blacks, African Americans living with HIV in Southern US.  Full Article

Genmab says U.S. FDA grants priority review for daratumumab in relapsed multiple myeloma
Friday, 7 Oct 2016 06:07pm EDT 

Genmab : u.s. Fda grants priority review for daratumumab in relapsed multiple myeloma . Sbla was submitted by genmab's licensing partner, janssen biotech, inc. In august 2016 . Pdufa date set at june 17, 2017 . Fda has assigned pdufa target date of february 17, 2017 to take a decision on daratumumab . Fda has assigned a prescription drug user fee act (pdufa) target date of february 17, 2017 . Sbla submission also included data from phase i study of daratumumab in combination with pomalidomide and dexamethasone .Pdufa date for combination of daratumumab with pomalidomide/dexamethasone is june 17, 2017.  Full Article

U.S. FDA warns about the risk of Hepatitis B
Tuesday, 4 Oct 2016 05:31pm EDT 

: U.S. FDA warns about the risk of Hepatitis B reactivating in some patients treated with direct-acting antivirals for Hepatitis C .Requiring a boxed warning about risk of HBV reactivation to be added to drug labels of direct-acting antiviral medicines for Hepatitis C virus.  Full Article

Judge tosses 53 plaintiffs' claims against J&J over Risperdal

Johnson & Johnson has convinced a federal judge that a recent U.S. Supreme Court ruling requires the dismissal of claims in Missouri state court by 53 out-of-state plaintiffs over injuries they blame on the antipsychotic drugs Risperdal and Invega.